The author is bearish on Ibiden, calling it overpriced and predicting market-share losses, and recommends going long AT&S, Kinsus, and Ajinomoto. The quoted analysis instead argues that tight high-end substrate capacity could support Ibiden’s growth and pricing, forecasting FY3/27–FY3/28 revenue growth of 35% and 30%, respectively.